furosemide has been researched along with Bronchopulmonary Dysplasia in 36 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When administered parenterally, furosemide, a loop diuretic, results in improved lung compliance and decreased airway resistance in infants with bronchopulmonary dysplasia (BPD)." | 9.08 | Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. ( Durand, M; Garg, M; Kugelman, A, 1997) |
| "0 mg of nebulized furosemide per kilogram of body weight on pulmonary functions were studied in eight preterm infants with bronchopulmonary dysplasia who were supported by mechanical ventilation." | 9.07 | Nebulized furosemide in infants with bronchopulmonary dysplasia. ( Ajayi, OA; Luayon, M; Pildes, RS; Rastogi, A, 1994) |
| "To test the hypothesis that alternate-day administration of furosemide will result in a sustained improvement in pulmonary function without causing alterations in electrolyte or mineral homeostasis, we conducted a randomized, double-blind, placebo-controlled study of 11 hospitalized, oxygen-dependent, spontaneously breathing infants with chronic bronchopulmonary dysplasia." | 9.06 | Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. ( Engelhardt, B; Hazinski, TA; Parker, RA; Rush, MG, 1990) |
| "To review the efficacy and safety of inhaled furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia (BPD) in preterm neonates receiving ventilator and oxygen support." | 8.80 | Aerosolized furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia in preterm neonates. ( Nahata, MC; Pai, VB, 2000) |
| "To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD)." | 7.91 | Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. ( Benjamin, DK; Clark, RH; Gayam, S; Gorham, D; Greenberg, RG; Laughon, M; Savage, D; Sholomon, A; Smith, PB; Tong, A, 2019) |
| "We studied the effects of a single dose of intravenous furosemide on the body water compartments of nine infants with bronchopulmonary dysplasia." | 7.67 | Effects of furosemide on body water compartments in infants with bronchopulmonary dysplasia. ( Bell, EF; O'Donovan, BH, 1989) |
| "Pulmonary and renal responses to furosemide were evaluated in ten infants with stage III-IV bronchopulmonary dysplasia." | 7.67 | Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia. ( Jain, R; Patel, H; Pildes, R; Yeh, TF, 1985) |
| "We studied the effects of furosemide on pulmonary mechanics in 10 infants with bronchopulmonary dysplasia aged 41 +/- 1 (SE) weeks post-conception, gestational age at birth 30 +/- 1 wk, birth weight 1370 +/- 200 gm." | 7.66 | Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. ( Kao, LC; Keens, TG; Platzker, AC; Sargent, CW; Warburton, D, 1983) |
| " There were no significant differences in the dosage of furosemide, gestational age, placement of umbilical venous catheters, or amount of total parenteral nutrition (TPN) between subjects with and without gallstones." | 5.28 | Cholelithiasis in infants receiving furosemide: a prospective study of the incidence and one-year follow-up. ( Molteni, RA; Randall, LH; Reid, BS; Shaddy, RE; Sturtevant, JE, 1992) |
| "When administered parenterally, furosemide, a loop diuretic, results in improved lung compliance and decreased airway resistance in infants with bronchopulmonary dysplasia (BPD)." | 5.08 | Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. ( Durand, M; Garg, M; Kugelman, A, 1997) |
| "0 mg of nebulized furosemide per kilogram of body weight on pulmonary functions were studied in eight preterm infants with bronchopulmonary dysplasia who were supported by mechanical ventilation." | 5.07 | Nebulized furosemide in infants with bronchopulmonary dysplasia. ( Ajayi, OA; Luayon, M; Pildes, RS; Rastogi, A, 1994) |
| "We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo." | 5.07 | Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. ( Birch, M; Durand, DJ; Kao, LC; McCrea, RC; Nickerson, BG; Powers, RJ, 1994) |
| "To test the hypothesis that alternate-day administration of furosemide will result in a sustained improvement in pulmonary function without causing alterations in electrolyte or mineral homeostasis, we conducted a randomized, double-blind, placebo-controlled study of 11 hospitalized, oxygen-dependent, spontaneously breathing infants with chronic bronchopulmonary dysplasia." | 5.06 | Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. ( Engelhardt, B; Hazinski, TA; Parker, RA; Rush, MG, 1990) |
| "To review the efficacy and safety of inhaled furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia (BPD) in preterm neonates receiving ventilator and oxygen support." | 4.80 | Aerosolized furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia in preterm neonates. ( Nahata, MC; Pai, VB, 2000) |
| "To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD)." | 3.91 | Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. ( Benjamin, DK; Clark, RH; Gayam, S; Gorham, D; Greenberg, RG; Laughon, M; Savage, D; Sholomon, A; Smith, PB; Tong, A, 2019) |
| "At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide." | 3.88 | Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants. ( Balevic, S; Benjamin, DK; Clark, RH; Goldberg, RN; Greenberg, RG; Ku, LC; Laughon, M; Smith, PB; Wang, LA; Zimmerman, KO, 2018) |
| "Renal response to furosemide following initial and chronic doses was investigated in premature infants with bronchopulmonary dysplasia." | 3.68 | Renal response to furosemide in very low birth weight infants during chronic administration. ( Chapron, DJ; Kramer, PA; Miceli, JJ; Mirochnick, MH; Raye, JR, 1990) |
| "The pharmacokinetics of furosemide were studied longitudinally during long-term administration in 10 very low birth weight infants with bronchopulmonary dysplasia." | 3.67 | Furosemide pharmacokinetics in very low birth weight infants. ( Chapron, DJ; Kramer, PA; Miceli, JJ; Mirochnick, MH; Raye, JR, 1988) |
| "Pulmonary and renal responses to furosemide were evaluated in ten infants with stage III-IV bronchopulmonary dysplasia." | 3.67 | Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia. ( Jain, R; Patel, H; Pildes, R; Yeh, TF, 1985) |
| "We studied the effects of furosemide on pulmonary mechanics in 10 infants with bronchopulmonary dysplasia aged 41 +/- 1 (SE) weeks post-conception, gestational age at birth 30 +/- 1 wk, birth weight 1370 +/- 200 gm." | 3.66 | Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. ( Kao, LC; Keens, TG; Platzker, AC; Sargent, CW; Warburton, D, 1983) |
| "Pulmonary edema has been demonstrated in the early stages of respiratory distress syndrome in premature infants." | 2.65 | Early furosemide therapy in premature infants (less than or equal to 2000 gm) with respiratory distress syndrome: a randomized controlled trial. ( Leu, ST; Pildes, RS; Raval, D; Shibli, A; Yeh, TF, 1984) |
| "Furosemide, because of its actions on the ubiquitous Na(+) -K(+) -2Cl(-) isoform cotransporter and its promotion of prostanoid production and release, also has non-diuretic effects on vascular smooth muscle, airways, the ductus arteriosus and theoretically the gastrointestinal tract." | 2.48 | Unexpected extra-renal effects of loop diuretics in the preterm neonate. ( Cotton, R; Reese, J; Suarez, S, 2012) |
| "Furosemide was the most widely prescribed diuretic (1218 infants; 85%), although chlorothiazide had the longest median duration of use (21 days; 25th-75th percentile: 8-46 days)." | 1.39 | Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. ( Reagan, PB; Slaughter, JL; Stenger, MR, 2013) |
| " There were no significant differences in the dosage of furosemide, gestational age, placement of umbilical venous catheters, or amount of total parenteral nutrition (TPN) between subjects with and without gallstones." | 1.28 | Cholelithiasis in infants receiving furosemide: a prospective study of the incidence and one-year follow-up. ( Molteni, RA; Randall, LH; Reid, BS; Shaddy, RE; Sturtevant, JE, 1992) |
| "Though the coexistence of nephrolithiasis and cholelithiasis in premature infants is extremely rare, we report four patients seen in a two year period." | 1.28 | Coexisting nephrolithiasis and cholelithiasis in premature infants. ( Blickman, JG; Cleveland, RH; Herrin, JT; Jaramillo, D, 1991) |
| "All of the infants had hypoxemia with air-trapping in the chest at the time of admission to the hospital." | 1.27 | Antidiuretic hormone response in children with bronchopulmonary dysplasia during episodes of acute respiratory distress. ( Eid, N; Herrod, L; Parekh, A; Rao, M; Steiner, P, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (38.89) | 18.7374 |
| 1990's | 12 (33.33) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 8 (22.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Segar, JL | 3 |
| Wang, LA | 1 |
| Smith, PB | 3 |
| Laughon, M | 2 |
| Goldberg, RN | 1 |
| Ku, LC | 1 |
| Zimmerman, KO | 1 |
| Balevic, S | 1 |
| Clark, RH | 3 |
| Benjamin, DK | 2 |
| Greenberg, RG | 2 |
| Gayam, S | 1 |
| Savage, D | 1 |
| Tong, A | 1 |
| Gorham, D | 1 |
| Sholomon, A | 1 |
| Jobe, AH | 1 |
| Slaughter, JL | 1 |
| Stenger, MR | 1 |
| Reagan, PB | 1 |
| Laughon, MM | 1 |
| Chantala, K | 1 |
| Aliaga, S | 1 |
| Herring, AH | 1 |
| Hornik, CP | 1 |
| Hughes, R | 1 |
| Jensen, EA | 1 |
| White, AM | 1 |
| Liu, P | 1 |
| Yee, K | 1 |
| Waber, B | 1 |
| Monk, HM | 1 |
| Zhang, H | 1 |
| Cotton, R | 1 |
| Suarez, S | 1 |
| Reese, J | 1 |
| Yeh, TF | 2 |
| Shibli, A | 1 |
| Leu, ST | 1 |
| Raval, D | 1 |
| Pildes, RS | 2 |
| Kao, LC | 2 |
| Warburton, D | 1 |
| Sargent, CW | 1 |
| Platzker, AC | 1 |
| Keens, TG | 1 |
| Finberg, L | 1 |
| Noe, HN | 1 |
| Bryant, JF | 1 |
| Roy, S | 1 |
| Stapleton, FB | 1 |
| Callahan, J | 1 |
| Haller, JO | 1 |
| Cacciarelli, AA | 1 |
| Slovis, TL | 1 |
| Friedman, AP | 1 |
| Guignard, JP | 1 |
| Dubourg, L | 1 |
| Gouyon, JB | 1 |
| Shankaran, S | 1 |
| Liang, KC | 1 |
| Ilagan, N | 1 |
| Fleischmann, L | 1 |
| Rastogi, A | 1 |
| Luayon, M | 1 |
| Ajayi, OA | 1 |
| Durand, DJ | 1 |
| McCrea, RC | 1 |
| Birch, M | 1 |
| Powers, RJ | 1 |
| Nickerson, BG | 1 |
| Kugelman, A | 1 |
| Durand, M | 1 |
| Garg, M | 1 |
| Prabhu, VG | 1 |
| Pai, VB | 1 |
| Nahata, MC | 1 |
| Randall, LH | 1 |
| Shaddy, RE | 1 |
| Sturtevant, JE | 1 |
| Reid, BS | 1 |
| Molteni, RA | 1 |
| Robillard, JE | 1 |
| Johnson, KJ | 1 |
| Bell, EF | 2 |
| Chemtob, S | 2 |
| Blickman, JG | 1 |
| Herrin, JT | 1 |
| Cleveland, RH | 1 |
| Jaramillo, D | 1 |
| Rush, MG | 1 |
| Engelhardt, B | 2 |
| Parker, RA | 1 |
| Hazinski, TA | 2 |
| Mirochnick, MH | 2 |
| Miceli, JJ | 2 |
| Kramer, PA | 2 |
| Chapron, DJ | 2 |
| Raye, JR | 2 |
| Stefano, JL | 1 |
| Bhutani, VK | 1 |
| O'Donovan, BH | 1 |
| Perlman, JM | 1 |
| Moore, V | 1 |
| Siegel, MJ | 1 |
| Dawson, J | 1 |
| Bunyapen, C | 1 |
| Howell, CG | 1 |
| Kanto, WP | 1 |
| Kenney, IJ | 1 |
| Aiken, CG | 1 |
| Lenney, W | 1 |
| Aranda, JV | 1 |
| Laudignon, N | 1 |
| Sasyniuk, BI | 1 |
| Elliott, S | 1 |
| Rao, M | 1 |
| Eid, N | 1 |
| Herrod, L | 1 |
| Parekh, A | 1 |
| Steiner, P | 1 |
| Patel, H | 1 |
| Jain, R | 1 |
| Pildes, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Retrospective Chart Review Evaluating the Impact of Steroid, Diuretic, and Fluid Use Practice Trends in Extreme Premature Infants at Risk for Bronchopulmonary Dysplasia (BPD) at a Single Center Neonatal Intensive Care Unit[NCT04971694] | 175 participants (Anticipated) | Observational | 2021-09-08 | Recruiting | |||
| Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease[NCT01721655] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2012-10-31 | Recruiting | ||
| Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis[NCT02469597] | Phase 2 | 46 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02469597)
Timeframe: Participants will be followed for the duration of hospital stay up to 1 week
| Intervention | Days (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | 3.1 |
| Placebo | 3.0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.14 |
| Placebo | 0.2 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.19 |
| Placebo | 0.29 |
(NCT02469597)
Timeframe: Within 72 hours of medication administration
| Intervention | participants (Number) |
|---|---|
| Single Dose of Furosemide | 0 |
| Placebo | 0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -3.7 |
| Placebo | -1.7 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -2.8 |
| Placebo | -5.4 |
5 reviews available for furosemide and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Neonatal diuretic therapy: furosemide, thiazides, and spironolactone.
Topics: Bronchopulmonary Dysplasia; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Infant, Newbor | 2012 |
Unexpected extra-renal effects of loop diuretics in the preterm neonate.
Topics: Biomarkers; Bronchopulmonary Dysplasia; Bumetanide; Central Nervous System; Diuretics; Ductus Arteri | 2012 |
[Diuretics in the neonatal period].
Topics: Benzothiadiazines; Bronchopulmonary Dysplasia; Diuretics; Furosemide; Heart Failure; Humans; Infant, | 1995 |
Aerosolized furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia in preterm neonates.
Topics: Administration, Inhalation; Aerosols; Bronchopulmonary Dysplasia; Diuretics; Furosemide; Humans; Inf | 2000 |
Furosemide and vitamin E. Two problem drugs in neonatology.
Topics: Acid-Base Imbalance; Anemia; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Diuresis; Ductus Arter | 1986 |
8 trials available for furosemide and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Early furosemide therapy in premature infants (less than or equal to 2000 gm) with respiratory distress syndrome: a randomized controlled trial.
Topics: Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductus Arteriosus, Patent; Furosemide; Humans; | 1984 |
Mineral excretion following furosemide compared with bumetanide therapy in premature infants.
Topics: Bronchopulmonary Dysplasia; Bumetanide; Calcium; Chlorides; Cross-Over Studies; Diuresis; Furosemide | 1995 |
Nebulized furosemide in infants with bronchopulmonary dysplasia.
Topics: Airway Resistance; Body Weight; Bronchopulmonary Dysplasia; Dose-Response Relationship, Drug; Female | 1994 |
Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
Topics: Analysis of Variance; Bronchopulmonary Dysplasia; Chlorothiazide; Double-Blind Method; Drug Therapy, | 1994 |
Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia.
Topics: Administration, Inhalation; Birth Weight; Blood Gas Analysis; Bronchopulmonary Dysplasia; Cross-Over | 1997 |
Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Diuresis; Drug Therapy, Combination; Drug Tolerance; Furosemide; Humans; | 1992 |
Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia.
Topics: Airway Resistance; Bronchopulmonary Dysplasia; Calcium; Chronic Disease; Clinical Trials as Topic; D | 1990 |
Short- and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia.
Topics: Airway Resistance; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Furosemide; Humans; Infant; | 1986 |
23 other studies available for furosemide and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Rethinking furosemide use for infants with bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Chronic Disease; Furosemide; Hospitalization; Humans; Infant, Newborn; I | 2020 |
Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants.
Topics: Bronchopulmonary Dysplasia; Diuretics; Evoked Potentials, Auditory, Brain Stem; Female; Furosemide; | 2018 |
Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.
Topics: Birth Weight; Bronchopulmonary Dysplasia; Drug Administration Schedule; Female; Furosemide; Gestatio | 2019 |
Off-Label Drugs in Neonatology: Analyses Using Large Data Bases.
Topics: Bronchopulmonary Dysplasia; Furosemide; Humans; Infant; Infant, Newborn; Infant, Premature; Neonatol | 2019 |
Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Chlorothiazide; Cohort Studies; Databases, Factual; Diuretics; Drug Admi | 2013 |
Diuretic exposure in premature infants from 1997 to 2011.
Topics: Acetazolamide; Amiloride; Bronchopulmonary Dysplasia; Chlorothiazide; Cohort Studies; Diazoxide; Diu | 2015 |
Determinants of Severe Metabolic Bone Disease in Very Low-Birth-Weight Infants with Severe Bronchopulmonary Dysplasia Admitted to a Tertiary Referral Center.
Topics: Birth Weight; Bone Diseases, Metabolic; Bronchopulmonary Dysplasia; Comorbidity; Female; Furosemide; | 2016 |
Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia.
Topics: Airway Resistance; Bronchopulmonary Dysplasia; Chronic Disease; Furosemide; Humans; Infant, Newborn; | 1983 |
Furosemide--uses, abuses, and unsolved puzzles.
Topics: Bronchopulmonary Dysplasia; Furosemide; Humans; Infant, Newborn | 1983 |
Urolithiasis in pre-term neonates associated with furosemide therapy.
Topics: Bronchopulmonary Dysplasia; Calcium; Furosemide; Humans; Infant, Newborn; Kidney Calculi; Male; Radi | 1984 |
Cholelithiasis in infants: association with total parenteral nutrition and furosemide.
Topics: Bronchopulmonary Dysplasia; Cholelithiasis; Female; Furosemide; Humans; Infant, Newborn; Male; Paren | 1982 |
Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia.
Topics: Administration, Inhalation; Bronchi; Bronchopulmonary Dysplasia; Diuretics; Furosemide; Humans; Infa | 1997 |
Cholelithiasis in infants receiving furosemide: a prospective study of the incidence and one-year follow-up.
Topics: Bronchopulmonary Dysplasia; Catheterization; Cholelithiasis; Follow-Up Studies; Furosemide; Gallblad | 1992 |
Coexisting nephrolithiasis and cholelithiasis in premature infants.
Topics: Bronchopulmonary Dysplasia; Cholelithiasis; Female; Furosemide; Humans; Infant, Newborn; Infant, Pre | 1991 |
Renal response to furosemide in very low birth weight infants during chronic administration.
Topics: Bronchopulmonary Dysplasia; Chromatography, High Pressure Liquid; Diuresis; Drug Administration Sche | 1990 |
Role of furosemide therapy after booster-packed erythrocyte transfusions in infants with bronchopulmonary dysplasia.
Topics: Administration, Oral; Blood Transfusion; Bronchopulmonary Dysplasia; Erythrocyte Transfusion; Furose | 1990 |
Effects of furosemide on body water compartments in infants with bronchopulmonary dysplasia.
Topics: Body Fluid Compartments; Body Fluids; Body Water; Bronchopulmonary Dysplasia; Furosemide; Humans; In | 1989 |
Is chloride depletion an important contributing cause of death in infants with bronchopulmonary dysplasia?
Topics: Acid-Base Imbalance; Body Weight; Bronchopulmonary Dysplasia; Cardiomegaly; Chlorides; Furosemide; H | 1986 |
Cholecystitis in a preterm infant.
Topics: Anti-Bacterial Agents; Bronchopulmonary Dysplasia; Cholecystitis; Cholelithiasis; Diagnosis, Differe | 1986 |
Frusemide-induced nephrocalcinosis in very low birth weight infants.
Topics: Bronchopulmonary Dysplasia; Female; Furosemide; Humans; Infant, Low Birth Weight; Infant, Newborn; M | 1988 |
Furosemide pharmacokinetics in very low birth weight infants.
Topics: Age Factors; Bronchopulmonary Dysplasia; Furosemide; Half-Life; Humans; Infant, Low Birth Weight; In | 1988 |
Antidiuretic hormone response in children with bronchopulmonary dysplasia during episodes of acute respiratory distress.
Topics: Bronchopulmonary Dysplasia; Female; Furosemide; Humans; Hyponatremia; Hypoxia; Infant; Infant, Newbo | 1986 |
Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Calcium; Chlorides; Furosemide; Humans; Infant; Infant, Newborn; Kidney; | 1985 |